Novo Nordisk’s Torrid Week Erases Last of Wegovy-Fueled Gains

Wegovy pills
Photographer: George Frey/Bloomberg

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Jonas Ekblom

February 27, 2026 at 10:56 AM UTC

The weight loss-fueled gains of Danish drugmaker Novo Nordisk A/S are officially a thing of the past.

The stock this week wiped out the last of the yearslong surge that followed the 2021 US approval of its Wegovy obesity drug, after a next-generation shot delivered less weight loss than that of its main rival.